Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The mouse osteosarcoma C22LR was irradiated with a single X-ray dose of 1000 or 1500 rad (to prevent rapid growth) and then with fractionated doses of 300 or 600 rad each. Half the mice were given 0.8 mg/g of misonidazole 1 h before irradiation. Tumour growth delay was determined. The radiosensitizer did enhance the effect of small (300 rad) doses per fraction, as well as that of 600 rad doses.
 ...
PMID:Misonidazole with small dose fractions in an experimental osteosarcoma. 27 40

Detailed analysis of the roentgen findings in 30 well-documented cases of parosteal osteogenic sarcoma (POS) was made. The supposedly characteristic periosteal lucency (cleavage plane) was found in only 30% of the patients. While most tumors were densely ossified, the radiodensity was uniform in only 27%. The surface of the tumor was usually irregular and a truly smooth surface was seen in only 24%. Four patients underwent arteriography; there was vessel displacement by the tumors but all were avascular. No correlation between the histologic grade of tumor and roentgen signs was found.
 ...
PMID:Parosteal (juxtacortical) osteogenic sarcoma. A roentgenological study of 30 patients. 27 41

Interferon was used to treat C57BL/6 female mice inoculated with a continuous line of murine osteogenic sarcoma cells. A short 7-day course of 30,000--60,000 U/day of tpe I interferon either completely inhibited or delayed the appearance of tumors in experimental animals. The therapeutic efficacy of type I interferon was compared with murine serum that contained type II interferon as well as other lymphokine activity. Tumor development was strikingly inhibited in animals treated for 7 days with serum containing only 600 U of type II interferon. Inhibition of tumor development was thus achieved with 100-fold less interferon than that required with type I preparation.
 ...
PMID:Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. 27 65

We describe the case history of a 13 years old boy who developed osteogenic sarcoma of the left thigh, six years after diagnosis of osteogenesis imperfecta tarda with a positive family history. Only four other patients with this disease combination are reported in the literature. Preoperative treatment with high-dose Methotrexate caused marked tumor regression, as shown at examination of amputation material. The inter-relationships between the two disorders are discussed and the literature is briefly reviewed.
 ...
PMID:Osteogenic sarcoma complicating osteogenesis imperfecta tarda. 27 54

Only 12% of 50 patients lived 5 years or longer. Those who survived the longest were those with the tumor in the distal part of the lower extremity, with a well differentiated or chondroblastic tumor, or those who underwent radical surgery. Patients treated with surgery and chemotherapy lived about 1.5 months longer than those treated with sugery alone and about 1.2 months longer than those who had radiation included in the therapy. For a patient with a diagnosis of osteosarcoma, the prognosis was to be grave, no matter which methods of treatment were used.
 ...
PMID:Osteosarcoma: a review of 50 patients treated at the University of Alabama in Birmingham Medical Center between 1944 and 1975. 28 Apr 24

Results of surgery and chemotherapy in osteosarcoma are based on a retrospective investigation of 122 patients from 1930 till 1978 treated at the Orthopaedic Department of Vienna University and documented at the Viennese Bone Tumour Registry. Adequate surgery is considered to be the radical elimination of the tumour in an oncological sense, e.g. amputation or resection. Our own patients were examined in this light and different forms of chemotherapy are compared and their efficacy as adjuvant treatment is evaluated. The turning point in the prognosis of osteosarcoma came with the introduction of high-dose methotrexate therapy (HDMTX) in 1972 and which has been employed at the Orthopaedic Department of Vienna University since 1975. So far, HDMTX has been used in the management of 18 patients and the short-term results confirm the excellent results reported in the literature. The consequent change in policy with regard to the current surgical approach to osteosarcoma is discussed in detail.
 ...
PMID:[Osteosarcoma 1978 a turning point in prognosis through adjuvant chemotherapy following adequate surgery (author's transl)]. 28 Oct 55

A case of osteosarcoma arising in the soft tissue of the larynx in an elderly man is presented with light and electron microscopic documentation. The patient developed chronic hoarseness and a recurring polypoid laryngeal tumor, causing acute airway obstruction. He was treated by total laryngectomy, but he died with multiple pulmonary metastases within three months of laryngectomy. This is the third (or possibly fourth) recorded case of osteosarcoma arising in the soft tissues of the larynx, and the previous cases were clinically and pathologically similar to this one. The prognosis of sarcoma of the larynx is poor but may be improved with early recognition and adequate surgical excision.
 ...
PMID:Osteosarcoma of the soft tissue of the larynx: report of a case with light and electron microscopic studies. 28 Dec 60

Murine interferon inhibited the growth of a continuous line of osteogenic sarcoma cells in tissue culture. Inhibition of tumor cell growth was documented by decreased clone formation in liquid medium, decreased tumor cell counts in monolayer cultures, suppression of colony formation in semi-solid agar, and decreased uptake of 3H-thymidine by the osteogenic sarcoma cells in culture. The capacity of anti-interferon antibody to block the tumor cell growth inhibitory activity of the interferon preparation suggested that interferon itself is the biologically active component of the interferon preparations. In vivo, a 7-day course of 30,000-60,000 units/day of type I interferon prepared in cell cultures either completely inhibited or delayed the appearance of tumors in experimental animals inoculated with osteogenic sarcoma cells by the sc route. The therapeutic efficacy of a preparation of murine sera containing type II interferon as well as other lymphokine activity was compared with the type I interferon preparation. Animals treated with 600 units of type II interferon were protected against tumor development as effectively as with 60,000 units/day of type I.
 ...
PMID:Antitumor activity of interferon against murine osteogenic sarcoma in vitro and in vivo. 28 6

An aqueous-ether extract of Brucella abortus, Bru-Pel, enhanced resistance of mice to a transplantable osteogenic sarcoma (OGS). The results presented in this report suggest that Bru-Pel is an effective immunomodulator and that one mechanism through which it enhances host resistance is activation of phagocytic cells of the reticuloendothelial system. Peritoneal macrophages from mice inoculated with Bru-Pel 14 days previously were cytotoxic for OGS cells in vitro, limited the multiplication of vaccinia virus in cell cultures, and demonstrated increased chemiluminescence during phagocytosis. Furthermore, Bru-Pel enhanced host resistance to Listeria monocytogenes, in addition to viral infections and a transplantable tumor. These results support the hypothesis that Bru-Pel shares a number of characteristics with other recognized immunomodulating agents and suggest that further studies are warranted to better define the potential of Bru-Pel for immunotherapeutic regimens in man.
 ...
PMID:Activation of reticuloendothelial system macrophages and enhancement of host resistance to a transplantable osteogenic sarcoma in mice by an extract of Brucella abortus. 28 7

Giant-cell tumor of the jaw presents difficulty in diagnosis. It is rare in the head and neck regions and may resemble, clinically and histologically, other types of jaw lesion. However, histologic study may distinguish this lesion from a giant-cell granuloma, an osteogenic sarcoma, and most epulides. Adequate surgical excision with a long-term follow-up is the recommended treatment of choice.
 ...
PMID:Giant-cell tumor of the maxilla. Report of a case. 28 40


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>